azacitidine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
nucleosides antiviral or antineoplastic agents, cytarabine or azacitidine derivatives 25 320-67-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • 5-azacytidine
  • azacitidine
  • azacytidine
  • ladakamycin
  • ledakamycin
  • vidaza
  • U-18496
A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
  • Molecular weight: 244.21
  • Formula: C8H12N4O5
  • CLOGP: -2.20
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 4
  • TPSA: 140.97
  • ALOGS: -1.30
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 89 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 62 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 177.10 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.47 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 35 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.36 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 21, 2011 PMDA Nippon Shinyaku Co., Ltd.
Aug. 2, 2019 EMA Celgene Europe BV
May 19, 2004 FDA CELGENE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 1634.10 22.16 732 15754 117717 63354819
Acute myeloid leukaemia 687.22 22.16 231 16255 16916 63455620
Death 475.29 22.16 532 15954 373849 63098687
Thrombocytopenia 473.52 22.16 357 16129 150800 63321736
Pancytopenia 385.75 22.16 265 16221 96668 63375868
Acute myeloid leukaemia recurrent 361.41 22.16 84 16402 1539 63470997
Neutropenia 352.34 22.16 320 16166 174685 63297851
Sepsis 352.18 22.16 302 16184 152821 63319715
Pneumonia 348.35 22.16 504 15982 456263 63016273
Myelosuppression 264.02 22.16 127 16359 23576 63448960
Septic shock 222.81 22.16 164 16322 66465 63406071
Platelet count decreased 201.87 22.16 196 16290 115926 63356610
Neutrophil count decreased 197.99 22.16 143 16343 56263 63416273
Blast cell count increased 182.31 22.16 38 16448 408 63472128
Cytopenia 166.06 22.16 74 16412 11527 63461009
Bronchopulmonary aspergillosis 162.98 22.16 67 16419 8568 63463968
Myelodysplastic syndrome transformation 154.42 22.16 33 16453 403 63472133
Pyrexia 154.06 22.16 361 16125 470117 63002419
Anaemia 145.12 22.16 267 16219 293163 63179373
Transformation to acute myeloid leukaemia 122.66 22.16 25 16461 238 63472298
Pain 119.24 22.16 24 16462 740604 62731932
Pneumonitis 113.81 22.16 85 16401 35137 63437399
Pneumonia fungal 108.66 22.16 44 16442 5411 63467125
White blood cell count decreased 94.41 22.16 146 16340 138958 63333578
Arthralgia 84.49 22.16 22 16464 569688 62902848
Respiratory failure 82.18 22.16 116 16370 101742 63370794
Multiple organ dysfunction syndrome 80.60 22.16 86 16400 56666 63415870
Tumour lysis syndrome 78.88 22.16 41 16445 8949 63463587
Differentiation syndrome 78.18 22.16 23 16463 1080 63471456
Neutropenic sepsis 77.37 22.16 50 16436 16388 63456148
Acute febrile neutrophilic dermatosis 76.94 22.16 29 16457 2945 63469591
Myelodysplastic syndrome 74.07 22.16 49 16437 16705 63455831
Aspergillus infection 68.41 22.16 36 16450 8057 63464479
Headache 65.57 22.16 42 16444 633199 62839337
Cerebral haemorrhage 65.10 22.16 58 16428 30671 63441865
Leukaemia 63.94 22.16 28 16458 4180 63468356
Bone marrow failure 59.52 22.16 54 16432 29236 63443300
Joint swelling 58.35 22.16 8 16478 327658 63144878
Disease progression 58.31 22.16 110 16376 122648 63349888
Acute graft versus host disease 56.25 22.16 26 16460 4402 63468134
Infection 54.14 22.16 156 16330 229017 63243519
Swelling 53.34 22.16 5 16481 275373 63197163
Graft versus host disease in skin 52.97 22.16 22 16464 2883 63469653
Abdominal discomfort 52.29 22.16 10 16476 320875 63151661
Allogenic stem cell transplantation 51.67 22.16 10 16476 71 63472465
Pneumonia adenoviral 51.49 22.16 11 16475 134 63472402
Cardiac failure 51.46 22.16 87 16399 89055 63383481
Agranulocytosis 50.40 22.16 46 16440 25088 63447448
Subdural haematoma 49.46 22.16 36 16450 14292 63458244
Myelofibrosis 49.01 22.16 17 16469 1360 63471176
Product dose omission issue 48.92 22.16 3 16483 234310 63238226
Soft tissue infection 48.70 22.16 19 16467 2118 63470418
Nasopharyngitis 48.23 22.16 5 16481 254252 63218284
Drug hypersensitivity 47.91 22.16 11 16475 310676 63161860
Therapy non-responder 47.74 22.16 77 16409 75824 63396712
Graft versus host disease in gastrointestinal tract 47.41 22.16 21 16465 3220 63469316
Alopecia 46.33 22.16 15 16471 337521 63135015
Peripheral swelling 46.15 22.16 7 16479 265935 63206601
Stenotrophomonas infection 46.12 22.16 18 16468 2009 63470527
Bacteraemia 45.45 22.16 37 16449 17311 63455225
Maternal exposure during pregnancy 45.39 22.16 3 16483 220059 63252477
Leukopenia 45.36 22.16 76 16410 77214 63395322
Escherichia sepsis 44.39 22.16 23 16463 4984 63467552
Organising pneumonia 44.06 22.16 24 16462 5752 63466784
Refractory anaemia with an excess of blasts 43.78 22.16 12 16474 435 63472101
Acute myeloid leukaemia refractory 42.97 22.16 9 16477 99 63472437
Enterococcal infection 42.26 22.16 26 16460 7822 63464714
Hypertension 40.89 22.16 11 16475 279292 63193244
Adenoviral hepatitis 40.37 22.16 11 16475 390 63472146
Hypersensitivity 40.17 22.16 13 16473 292672 63179864
Weight increased 38.69 22.16 10 16476 260782 63211754
Cellulitis 38.34 22.16 73 16413 81885 63390651
Periorbital cellulitis 38.25 22.16 12 16474 701 63471835
Graft versus host disease 37.94 22.16 23 16463 6740 63465796
Fatigue 35.99 22.16 115 16371 887913 62584623
Chloroma 35.71 22.16 9 16477 234 63472302
Infusion related reaction 35.32 22.16 10 16476 245511 63227025
Toxic neuropathy 35.11 22.16 10 16476 418 63472118
Dizziness 33.95 22.16 37 16449 429888 63042648
Liver abscess 33.90 22.16 16 16470 2838 63469698
Condition aggravated 33.58 22.16 33 16453 402184 63070352
Pulmonary sepsis 32.37 22.16 13 16473 1563 63470973
Haematotoxicity 31.10 22.16 23 16463 9353 63463183
Anxiety 31.03 22.16 9 16477 217532 63255004
Full blood count decreased 31.01 22.16 36 16450 25988 63446548
Graft versus host disease in liver 30.88 22.16 10 16476 647 63471889
Drug intolerance 29.81 22.16 22 16464 308639 63163897
Exposure during pregnancy 29.63 22.16 3 16483 155544 63316992
Haemoglobin decreased 29.56 22.16 94 16392 145391 63327145
Pseudomonas infection 29.55 22.16 24 16462 11189 63461347
Staphylococcal sepsis 29.37 22.16 21 16465 8107 63464429
Off label use 28.79 22.16 284 16202 674178 62798358
Dyspnoea 28.62 22.16 83 16403 661230 62811306
Pleural effusion 28.61 22.16 70 16416 93140 63379396
Pericardial effusion 28.41 22.16 37 16449 30021 63442515
Iron overload 27.90 22.16 10 16476 881 63471655
Discomfort 27.69 22.16 5 16481 167369 63305167
Bone marrow necrosis 27.45 22.16 6 16480 82 63472454
Disseminated intravascular coagulation 27.25 22.16 29 16457 19022 63453514
Fusarium infection 27.01 22.16 9 16477 637 63471899
Pain in extremity 26.73 22.16 28 16458 331458 63141078
Pseudomonal skin infection 26.25 22.16 4 16482 4 63472532
Bacterial sepsis 26.24 22.16 15 16471 3943 63468593
Leukocytosis 26.20 22.16 33 16453 25902 63446634
Hypoaesthesia 25.85 22.16 6 16480 168387 63304149
Therapeutic product effect decreased 25.75 22.16 9 16477 193178 63279358
Renal tubular disorder 25.75 22.16 13 16473 2669 63469867
Portal vein cavernous transformation 25.40 22.16 6 16480 118 63472418
Rash 25.27 22.16 69 16417 560802 62911734
Pseudomonal bacteraemia 25.27 22.16 11 16475 1617 63470919
Adenovirus infection 24.94 22.16 14 16472 3557 63468979
Renal tubular acidosis 24.87 22.16 11 16475 1681 63470855
Bacillus infection 24.57 22.16 9 16477 844 63471692
Minimal residual disease 24.51 22.16 6 16480 138 63472398
Febrile bone marrow aplasia 24.36 22.16 18 16468 7307 63465229
Constipation 24.21 22.16 119 16367 224824 63247712
Insomnia 23.99 22.16 13 16473 215239 63257297
Leukaemia recurrent 23.95 22.16 10 16476 1328 63471208
Abdominal pain upper 23.70 22.16 12 16474 206432 63266104
Intestinal ulcer 23.44 22.16 10 16476 1401 63471135
Klebsiella sepsis 23.14 22.16 10 16476 1445 63471091
COVID-19 pneumonia 22.79 22.16 23 16463 14186 63458350
Acute erythroid leukaemia 22.70 22.16 5 16481 71 63472465
Subarachnoid haemorrhage 22.69 22.16 23 16463 14260 63458276
Acute graft versus host disease in skin 22.67 22.16 13 16473 3439 63469097
Colitis 22.41 22.16 43 16443 48485 63424051

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 1875.17 18.21 1196 24824 135653 34795258
Acute myeloid leukaemia 858.41 18.21 367 25653 17903 34913008
Pneumonia 558.18 18.21 976 25044 361651 34569260
Sepsis 457.03 18.21 589 25431 165972 34764939
Neutrophil count decreased 401.08 18.21 320 25700 50784 34880127
Death 390.98 18.21 889 25131 397160 34533751
Neutropenia 367.84 18.21 514 25506 156264 34774647
Platelet count decreased 333.39 18.21 427 25593 119290 34811621
Acute myeloid leukaemia recurrent 297.93 18.21 96 25924 2074 34928837
Pancytopenia 270.33 18.21 343 25677 94814 34836097
Thrombocytopenia 266.48 18.21 442 25578 155805 34775106
Blast cell count increased 261.70 18.21 74 25946 1004 34929907
Myelosuppression 243.11 18.21 161 25859 19104 34911807
Cytopenia 241.50 18.21 138 25882 12585 34918326
Tumour lysis syndrome 238.41 18.21 152 25868 16907 34914004
Pneumonia fungal 226.38 18.21 109 25911 6991 34923920
Septic shock 221.59 18.21 270 25750 71564 34859347
White blood cell count decreased 201.31 18.21 298 25722 95147 34835764
Transformation to acute myeloid leukaemia 200.94 18.21 56 25964 718 34930193
Anaemia 190.71 18.21 487 25533 232848 34698063
Infection 183.33 18.21 278 25742 90637 34840274
Myelodysplastic syndrome transformation 178.55 18.21 45 25975 379 34930532
Myelodysplastic syndrome 145.56 18.21 118 25902 19090 34911821
Pyrexia 138.81 18.21 551 25469 332462 34598449
Bronchopulmonary aspergillosis 132.60 18.21 100 25920 14559 34916352
Acute febrile neutrophilic dermatosis 117.27 18.21 42 25978 1261 34929650
Chronic myelomonocytic leukaemia 94.14 18.21 30 25990 624 34930287
Bacteraemia 93.51 18.21 93 25927 19624 34911287
Drug interaction 85.12 18.21 31 25989 225915 34704996
Neutropenic sepsis 74.82 18.21 70 25950 13697 34917214
Headache 69.87 18.21 31 25989 200604 34730307
Product dose omission issue 64.43 18.21 7 26013 119704 34811207
Blood product transfusion dependent 64.30 18.21 20 26000 383 34930528
Organising pneumonia 63.60 18.21 45 25975 5934 34924977
Toxicity to various agents 59.42 18.21 38 25982 200324 34730587
Febrile bone marrow aplasia 59.16 18.21 49 25971 8160 34922751
Completed suicide 57.54 18.21 4 26016 98164 34832747
Graft versus host disease in gastrointestinal tract 56.90 18.21 35 25985 3648 34927263
Disseminated intravascular coagulation 54.54 18.21 74 25946 21742 34909169
Cerebral haemorrhage 49.07 18.21 91 25929 34846 34896065
Pyoderma gangrenosum 48.74 18.21 23 25997 1408 34929503
Anxiety 48.30 18.21 8 26012 99420 34831491
Blood pressure increased 47.78 18.21 5 26015 88097 34842814
Arthralgia 46.74 18.21 35 25985 170006 34760905
Acute leukaemia 43.57 18.21 20 26000 1149 34929762
Therapy non-responder 42.99 18.21 92 25928 39054 34891857
Minimal residual disease 42.80 18.21 15 26005 422 34930489
Allogenic stem cell transplantation 42.21 18.21 10 26010 63 34930848
Soft tissue infection 41.68 18.21 24 25996 2216 34928695
Tremor 41.57 18.21 6 26014 82581 34848330
Neutropenic colitis 41.38 18.21 27 25993 3117 34927794
Overdose 40.67 18.21 9 26011 91050 34839861
Somnolence 40.51 18.21 16 26004 111100 34819811
Graft versus host disease in skin 40.50 18.21 29 25991 3896 34927015
Myelofibrosis 40.33 18.21 21 25999 1590 34929321
Drug hypersensitivity 40.19 18.21 6 26014 80523 34850388
Cardiac failure 40.13 18.21 154 25866 91094 34839817
Injection site reaction 40.09 18.21 49 25971 12984 34917927
Pneumonitis 39.97 18.21 82 25938 33796 34897115
Bone marrow failure 39.59 18.21 75 25945 29178 34901733
Pain in extremity 38.85 18.21 23 25997 126490 34804421
Escherichia sepsis 37.96 18.21 30 25990 4674 34926237
Graft versus host disease 37.93 18.21 43 25977 10526 34920385
Necrotising fasciitis 37.26 18.21 27 25993 3695 34927216
Pain 36.60 18.21 60 25960 204615 34726296
Weight increased 36.28 18.21 12 26008 93021 34837890
Haemoglobin abnormal 36.25 18.21 27 25993 3853 34927058
Dyspnoea 35.67 18.21 152 25868 376630 34554281
Anal abscess 35.33 18.21 33 25987 6440 34924471
Myositis 34.91 18.21 44 25976 12026 34918885
Leukaemia recurrent 34.66 18.21 19 26001 1596 34929315
Muscle spasms 34.34 18.21 7 26013 74994 34855917
Cellulitis 33.53 18.21 101 25919 52850 34878061
Peripheral swelling 33.31 18.21 8 26012 76533 34854378
Off label use 32.87 18.21 465 25555 419059 34511852
Enteritis infectious 32.28 18.21 17 26003 1317 34929594
General physical health deterioration 31.03 18.21 182 25838 128087 34802824
Disease progression 30.58 18.21 160 25860 107917 34822994
Leukocytosis 30.48 18.21 60 25960 24005 34906906
Hypoaesthesia 29.70 18.21 5 26015 61439 34869472
Acute myeloid leukaemia refractory 29.70 18.21 7 26013 43 34930868
Acute graft versus host disease 29.58 18.21 30 25990 6473 34924438
Paraesthesia 29.35 18.21 6 26014 64166 34866745
Depression 29.31 18.21 18 26002 97080 34833831
Hyperhidrosis 29.09 18.21 10 26010 75682 34855229
Dizziness 28.97 18.21 76 25944 218445 34712466
Escherichia bacteraemia 28.82 18.21 22 25998 3258 34927653
Aeromonas infection 28.78 18.21 10 26010 274 34930637
Aspergillus infection 28.27 18.21 40 25980 12214 34918697
Septal panniculitis 27.98 18.21 7 26013 57 34930854
Insomnia 27.74 18.21 22 25998 103885 34827026
Condition aggravated 27.70 18.21 64 25956 192132 34738779
Myalgia 27.68 18.21 14 26006 84096 34846815
Meningeal neoplasm 27.46 18.21 7 26013 62 34930849
Pseudomembranous colitis 27.38 18.21 20 26000 2771 34928140
Gait disturbance 26.80 18.21 15 26005 85125 34845786
Pulmonary sepsis 26.32 18.21 18 26002 2247 34928664
Weight decreased 25.98 18.21 58 25962 176243 34754668
Enterococcal infection 25.46 18.21 33 25987 9273 34921638
International normalised ratio increased 24.86 18.21 3 26017 47324 34883587
Pneumonia bacterial 24.84 18.21 37 25983 11835 34919076
Seizure 24.64 18.21 25 25995 104832 34826079
Graft versus host disease in liver 24.54 18.21 14 26006 1270 34929641
Urticaria 24.39 18.21 8 26012 62369 34868542
Febrile infection 24.35 18.21 17 26003 2194 34928717
Leukaemia 24.23 18.21 23 25997 4580 34926331
Pruritus 24.09 18.21 43 25977 141938 34788973
Iron overload 24.05 18.21 14 26006 1319 34929592
Epstein-Barr virus infection reactivation 23.72 18.21 13 26007 1091 34929820
Intentional product misuse 23.69 18.21 3 26017 45608 34885303
Malaise 23.59 18.21 66 25954 185759 34745152
Hypertension 23.44 18.21 41 25979 136402 34794509
Fatigue 23.31 18.21 171 25849 370482 34560429
Agitation 23.09 18.21 7 26013 57392 34873519
Rhabdomyolysis 22.95 18.21 11 26009 68152 34862759
Haemoglobin decreased 22.82 18.21 161 25859 120611 34810300
Chloroma 22.80 18.21 10 26010 516 34930395
Neutrophilic panniculitis 22.25 18.21 5 26015 24 34930887
Infusion related reaction 22.21 18.21 6 26014 53051 34877860
Epistaxis 22.14 18.21 94 25926 58157 34872754
Musculoskeletal stiffness 22.12 18.21 4 26016 46676 34884235
Clostridium difficile colitis 22.11 18.21 41 25979 15689 34915222
Colitis 22.03 18.21 70 25950 37680 34893231
Vision blurred 21.65 18.21 4 26016 45959 34884952
Pericardial effusion 21.58 18.21 53 25967 24609 34906302
Multiple organ dysfunction syndrome 21.40 18.21 113 25907 76453 34854458
Transplant 21.34 18.21 11 26009 815 34930096
Chest discomfort 21.31 18.21 7 26013 54523 34876388
Central nervous system leukaemia 21.23 18.21 8 26012 278 34930633
Joint swelling 21.20 18.21 9 26011 59881 34871030
Staphylococcal sepsis 21.05 18.21 31 25989 9813 34921098
Klebsiella sepsis 20.90 18.21 15 26005 2022 34928889
Wheezing 20.84 18.21 3 26017 41399 34889512
Platelet disorder 20.76 18.21 14 26006 1707 34929204
Blood glucose increased 20.65 18.21 12 26008 66706 34864205
Aplasia 20.56 18.21 21 25999 4567 34926344
Constipation 20.52 18.21 173 25847 136809 34794102
Full blood count decreased 20.41 18.21 43 25977 18045 34912866
Lower motor neurone lesion 20.29 18.21 5 26015 38 34930873
Acute graft versus host disease in skin 20.10 18.21 22 25998 5179 34925732
Bradycardia 20.09 18.21 16 26004 75402 34855509
Angiodysplasia 20.01 18.21 10 26010 694 34930217
Muscular weakness 20.00 18.21 15 26005 72882 34858029
Memory impairment 19.91 18.21 4 26016 43314 34887597
Catheter site infection 19.75 18.21 16 26004 2581 34928330
Abdominal discomfort 19.62 18.21 10 26010 59825 34871086
Asthma 19.48 18.21 4 26016 42652 34888259
Pseudomonal sepsis 19.20 18.21 18 26002 3529 34927382
Product reconstitution quality issue 19.19 18.21 6 26014 117 34930794
Emphysematous cholecystitis 19.16 18.21 5 26015 49 34930862
Subdural haematoma 19.06 18.21 45 25975 20376 34910535
Neutrophilic dermatosis 18.92 18.21 7 26013 231 34930680
Anorectal infection 18.86 18.21 7 26013 233 34930678
Rheumatoid arthritis 18.73 18.21 3 26017 38235 34892676
Feeling abnormal 18.69 18.21 12 26008 63223 34867688
Injection site vasculitis 18.61 18.21 3 26017 0 34930911
Second primary malignancy 18.57 18.21 26 25994 7860 34923051
Nasopharyngitis 18.44 18.21 15 26005 69953 34860958
Aspiration bone marrow abnormal 18.42 18.21 6 26014 134 34930777

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 3256.93 18.57 1750 35801 229249 79477588
Acute myeloid leukaemia 1094.34 18.57 445 37106 30440 79676397
Pneumonia 868.00 18.57 1289 36262 658957 79047880
Death 791.34 18.57 1139 36412 565375 79141462
Sepsis 772.85 18.57 782 36769 268646 79438191
Neutropenia 648.23 18.57 735 36816 286975 79419862
Thrombocytopenia 635.80 18.57 700 36851 264559 79442278
Acute myeloid leukaemia recurrent 621.23 18.57 169 37382 3214 79703623
Neutrophil count decreased 580.41 18.57 424 37127 93535 79613302
Pancytopenia 514.69 18.57 503 37048 165242 79541595
Myelosuppression 512.53 18.57 287 37264 40009 79666828
Platelet count decreased 508.44 18.57 538 37013 194126 79512711
Septic shock 423.32 18.57 395 37156 122406 79584431
Blast cell count increased 377.31 18.57 95 37456 1315 79705522
Cytopenia 372.38 18.57 185 37366 20198 79686639
Anaemia 350.98 18.57 695 36856 444320 79262517
Pneumonia fungal 321.16 18.57 139 37412 11071 79695766
Tumour lysis syndrome 313.81 18.57 174 37377 23765 79683072
Bronchopulmonary aspergillosis 286.63 18.57 160 37391 22134 79684703
Transformation to acute myeloid leukaemia 280.86 18.57 70 37481 927 79705910
White blood cell count decreased 279.08 18.57 391 37160 187897 79518940
Pyrexia 260.48 18.57 804 36747 677905 79028932
Myelodysplastic syndrome transformation 197.21 18.57 49 37502 640 79706197
Infection 168.01 18.57 359 37192 241353 79465484
Acute febrile neutrophilic dermatosis 165.60 18.57 64 37487 3808 79703029
Pain 153.49 18.57 70 37481 703732 79003105
Headache 150.56 18.57 60 37491 653712 79053125
Arthralgia 148.06 18.57 43 37508 571760 79135077
Myelodysplastic syndrome 141.49 18.57 116 37435 30185 79676652
Pneumonitis 140.61 18.57 158 37393 60702 79646135
Bacteraemia 133.40 18.57 116 37435 32708 79674129
Blood product transfusion dependent 125.11 18.57 31 37520 400 79706437
Therapy non-responder 119.49 18.57 180 37371 92125 79614712
Neutropenic sepsis 110.69 18.57 96 37455 26968 79679869
Completed suicide 101.94 18.57 3 37548 245764 79461073
Organising pneumonia 99.94 18.57 63 37488 10876 79695961
Cerebral haemorrhage 99.30 18.57 129 37422 57544 79649293
Drug hypersensitivity 94.66 18.57 14 37537 298902 79407935
Joint swelling 90.30 18.57 14 37537 288632 79418205
Escherichia sepsis 87.91 18.57 53 37498 8455 79698382
Product dose omission issue 87.29 18.57 8 37543 247529 79459308
Multiple organ dysfunction syndrome 86.17 18.57 181 37370 120065 79586772
Allogenic stem cell transplantation 82.50 18.57 17 37534 87 79706750
Aspergillus infection 82.48 18.57 70 37481 19091 79687746
Peripheral swelling 82.26 18.57 14 37537 269603 79437234
Respiratory failure 81.92 18.57 228 37323 180683 79526154
Rheumatoid arthritis 81.48 18.57 4 37547 208466 79498371
Differentiation syndrome 81.23 18.57 34 37517 2490 79704347
Cardiac failure 80.06 18.57 205 37346 154637 79552200
Graft versus host disease 79.69 18.57 62 37489 14964 79691873
Weight increased 79.13 18.57 17 37534 277369 79429468
Soft tissue infection 78.87 18.57 38 37513 3874 79702963
Febrile bone marrow aplasia 78.50 18.57 58 37493 12962 79693875
Drug interaction 77.61 18.57 50 37501 415133 79291704
Toxicity to various agents 75.80 18.57 53 37498 421487 79285350
Anxiety 75.60 18.57 13 37538 248499 79458338
Abdominal discomfort 74.36 18.57 14 37537 250713 79456124
Bone marrow failure 73.84 18.57 105 37446 51002 79655835
Disseminated intravascular coagulation 72.62 18.57 87 37464 35755 79671082
Pain in extremity 72.18 18.57 41 37510 364497 79342340
Cellulitis 71.07 18.57 158 37393 108902 79597935
Dyspnoea 71.05 18.57 190 37361 856835 78850002
Acute leukaemia 68.41 18.57 27 37524 1699 79705138
Cardiovascular disorder 67.83 18.57 61 37490 17964 79688873
Disease progression 66.10 18.57 214 37337 184148 79522689
Nasopharyngitis 65.74 18.57 19 37532 253862 79452975
Hypersensitivity 65.42 18.57 21 37530 262218 79444619
Leukaemia 64.05 18.57 38 37513 5887 79700950
Infusion related reaction 63.86 18.57 15 37536 230222 79476615
Dizziness 63.06 18.57 94 37457 526347 79180490
Enterococcal infection 62.92 18.57 55 37496 15605 79691232
Acute graft versus host disease 62.89 18.57 46 37505 10121 79696716
Swelling 62.37 18.57 13 37538 216698 79490139
Fatigue 62.30 18.57 227 37324 929500 78777337
Blood pressure increased 62.24 18.57 12 37539 211348 79495489
Myelofibrosis 61.92 18.57 28 37523 2472 79704365
Subdural haematoma 61.56 18.57 75 37476 31359 79675478
Graft versus host disease in liver 61.09 18.57 25 37526 1729 79705108
Neutropenic colitis 60.12 18.57 36 37515 5671 79701166
Stenotrophomonas infection 59.43 18.57 31 37520 3742 79703095
Pericardial effusion 58.14 18.57 89 37462 46148 79660689
Chloroma 56.59 18.57 19 37532 751 79706086
Graft versus host disease in gastrointestinal tract 56.55 18.57 36 37515 6320 79700517
Paraesthesia 56.39 18.57 8 37543 176315 79530522
Malaise 56.23 18.57 90 37461 489779 79217058
Tremor 56.10 18.57 7 37544 170076 79536761
Hypoaesthesia 55.38 18.57 9 37542 179343 79527494
Drug intolerance 54.75 18.57 28 37523 264091 79442746
Acute myeloid leukaemia refractory 54.28 18.57 13 37538 144 79706693
Pulmonary sepsis 54.22 18.57 29 37522 3683 79703154
Condition aggravated 53.00 18.57 97 37454 501027 79205810
Pruritus 52.75 18.57 65 37486 394583 79312254
Maternal exposure during pregnancy 52.15 18.57 3 37548 136535 79570302
Somnolence 51.55 18.57 24 37527 238957 79467880
Hypertension 51.48 18.57 48 37503 330944 79375893
Overdose 51.08 18.57 12 37539 184194 79522643
Gait disturbance 51.07 18.57 17 37534 207489 79499348
Necrotising fasciitis 50.70 18.57 33 37518 6017 79700820
Graft versus host disease in skin 50.58 18.57 33 37518 6040 79700797
Leukaemia recurrent 50.11 18.57 25 37526 2749 79704088
Constipation 48.58 18.57 262 37289 282788 79424049
Escherichia bacteraemia 48.26 18.57 33 37518 6529 79700308
Staphylococcal sepsis 47.99 18.57 46 37505 14680 79692157
Insomnia 47.89 18.57 28 37523 245142 79461695
Full blood count decreased 47.73 18.57 61 37490 26758 79680079
Minimal residual disease 47.35 18.57 15 37536 492 79706345
Iron overload 46.56 18.57 21 37530 1843 79704994
Asthma 45.94 18.57 5 37546 135090 79571747
Muscle spasms 45.36 18.57 13 37538 174717 79532120
Alopecia 44.37 18.57 27 37524 231328 79475509
Anal abscess 44.05 18.57 36 37515 9319 79697518
Klebsiella sepsis 43.58 18.57 24 37527 3228 79703609
Pyoderma gangrenosum 43.21 18.57 26 37525 4132 79702705
Epistaxis 42.27 18.57 132 37419 111383 79595454
Acute graft versus host disease in skin 41.48 18.57 32 37519 7626 79699211
General physical health deterioration 41.43 18.57 246 37305 274992 79431845
Agranulocytosis 40.99 18.57 75 37476 44955 79661882
Mobility decreased 40.35 18.57 5 37546 122170 79584667
Leukocytosis 40.35 18.57 73 37478 43382 79663455
Pneumonia bacterial 39.28 18.57 47 37504 19284 79687553
Haemoglobin decreased 39.04 18.57 207 37344 221912 79484925
Refractory anaemia with an excess of blasts 38.83 18.57 15 37536 891 79705946
Chest discomfort 38.25 18.57 9 37542 138035 79568802
Leukopenia 37.95 18.57 131 37420 116382 79590455
Therapeutic product effect decreased 37.65 18.57 15 37536 163848 79542989
Enteritis infectious 37.63 18.57 22 37529 3316 79703521
Transplant 37.28 18.57 15 37536 993 79705844
Haematotoxicity 37.03 18.57 41 37510 15478 79691359
Colitis 36.76 18.57 96 37455 73211 79633626
Off label use 36.40 18.57 614 36937 906601 78800236
Exposure during pregnancy 36.36 18.57 3 37548 101129 79605708
Myositis 36.34 18.57 45 37506 19123 79687714
Wheezing 35.68 18.57 6 37545 116658 79590179
Discomfort 35.18 18.57 8 37543 125609 79581228
Febrile infection 34.97 18.57 21 37530 3325 79703512
Periorbital cellulitis 34.87 18.57 14 37537 921 79705916
Blister 34.70 18.57 7 37544 119469 79587368
Fusarium infection 34.54 18.57 17 37534 1815 79705022
Aplasia 34.54 18.57 29 37522 7791 79699046
Feeling abnormal 34.30 18.57 16 37535 159183 79547654
Rash 34.29 18.57 148 37403 578210 79128627
Abdominal pain upper 34.15 18.57 33 37518 223786 79483051
Myalgia 33.76 18.57 23 37528 185618 79521219
Haemorrhage intracranial 33.75 18.57 51 37500 26142 79680695
Memory impairment 33.62 18.57 6 37545 111728 79595109
Hyperhidrosis 32.99 18.57 15 37536 151477 79555360
Haemoglobin abnormal 32.90 18.57 27 37524 7027 79699810
Chronic myelomonocytic leukaemia 32.42 18.57 13 37538 853 79705984
Clostridium difficile colitis 32.24 18.57 56 37495 32227 79674610
Weight decreased 32.22 18.57 75 37476 355123 79351714
Platelet disorder 32.22 18.57 19 37532 2910 79703927
Liver abscess 32.14 18.57 25 37526 6029 79700808
Loss of personal independence in daily activities 31.99 18.57 5 37546 102575 79604262
Depression 31.88 18.57 33 37518 216757 79490080
Palpitations 31.80 18.57 10 37541 126600 79580237
Pseudomonal sepsis 31.71 18.57 25 37526 6149 79700688
Pleural effusion 31.67 18.57 144 37407 145118 79561719
Pneumonia klebsiella 31.56 18.57 23 37528 5031 79701806
Pseudomonal bacteraemia 31.32 18.57 19 37532 3063 79703774
Pneumonia adenoviral 31.27 18.57 11 37540 501 79706336
Vision blurred 31.19 18.57 6 37545 105892 79600945
Intentional product misuse 31.17 18.57 4 37547 95161 79611676
Epstein-Barr virus infection reactivation 31.10 18.57 16 37535 1876 79704961
Sinusitis 30.79 18.57 28 37523 195473 79511364
Aeromonas infection 30.52 18.57 10 37541 366 79706471
Systemic candida 29.89 18.57 25 37526 6681 79700156
Anorectal infection 29.16 18.57 10 37541 422 79706415
Muscular weakness 29.11 18.57 20 37531 160709 79546128
Neutrophilic panniculitis 28.79 18.57 7 37544 83 79706754
Renal tubular disorder 28.54 18.57 24 37527 6462 79700375
Gastrooesophageal reflux disease 28.48 18.57 7 37544 104239 79602598
Cough 28.27 18.57 84 37467 366705 79340132
Dry mouth 28.11 18.57 4 37547 88015 79618822
Impaired healing 27.96 18.57 4 37547 87651 79619186
Migraine 27.89 18.57 4 37547 87489 79619348
Chest pain 27.74 18.57 57 37494 282247 79424590
Geotrichum infection 27.55 18.57 12 37539 969 79705868
Pseudomonas infection 27.36 18.57 41 37510 20862 79685975
Agitation 26.65 18.57 7 37544 99708 79607129
Balance disorder 26.31 18.57 7 37544 98850 79607987
Neutrophilic dermatosis 26.11 18.57 10 37541 580 79706257
Flushing 25.99 18.57 5 37546 88263 79618574
Septal panniculitis 25.82 18.57 7 37544 131 79706706
Bacterial sepsis 25.57 18.57 25 37526 8173 79698664
Cystitis haemorrhagic 25.00 18.57 26 37525 9146 79697691
Acute erythroid leukaemia 24.95 18.57 8 37543 273 79706564
COVID-19 pneumonia 24.94 18.57 47 37504 28802 79678035
Adenoviral hepatitis 24.93 18.57 11 37540 916 79705921
Mucormycosis 24.88 18.57 25 37526 8444 79698393
Blast cells present 24.82 18.57 11 37540 926 79705911
Toxic neuropathy 24.35 18.57 11 37540 969 79705868
Gingival bleeding 24.33 18.57 34 37517 16242 79690595
Cytomegalovirus infection reactivation 24.28 18.57 25 37526 8691 79698146
Interstitial lung disease 24.08 18.57 111 37440 112489 79594348
Diverticulitis 23.89 18.57 61 37490 45875 79660962
Pseudomembranous colitis 23.88 18.57 20 37531 5354 79701483
Klebsiella infection 23.74 18.57 33 37518 15687 79691150
Visual impairment 23.63 18.57 7 37544 92124 79614713
Leukaemic infiltration extramedullary 23.43 18.57 7 37544 188 79706649
Transfusion reaction 23.30 18.57 13 37538 1793 79705044
Fungal sepsis 23.14 18.57 13 37538 1817 79705020
Angiodysplasia 23.11 18.57 11 37540 1091 79705746
Lower motor neurone lesion 23.05 18.57 5 37546 34 79706803
Second primary malignancy 22.99 18.57 31 37520 14319 79692518
Cytogenetic abnormality 22.90 18.57 11 37540 1114 79705723
Injection site reaction 22.77 18.57 67 37484 54718 79652119
Helicobacter infection 22.66 18.57 3 37548 69701 79637136
Blood lactate dehydrogenase increased 22.47 18.57 54 37497 39116 79667721
Atypical pneumonia 22.14 18.57 21 37530 6615 79700222
Acute graft versus host disease in intestine 22.13 18.57 17 37534 4024 79702813
Tumour associated fever 22.07 18.57 10 37541 887 79705950
Central nervous system leukaemia 21.69 18.57 8 37543 418 79706419
Portal vein cavernous transformation 21.57 18.57 6 37545 124 79706713
Injury 21.57 18.57 5 37546 77491 79629346
Blood pressure systolic increased 21.50 18.57 3 37548 66983 79639854
Adverse drug reaction 21.24 18.57 3 37548 66389 79640448
Nasal congestion 21.18 18.57 5 37546 76547 79630290
Sleep disorder 21.10 18.57 7 37544 85670 79621167
Musculoskeletal pain 20.97 18.57 11 37540 102343 79604494
Pseudomonal skin infection 20.86 18.57 4 37547 13 79706824
Refractoriness to platelet transfusion 20.72 18.57 6 37545 144 79706693
Acinetobacter bacteraemia 20.72 18.57 7 37544 282 79706555
Haemophagocytic lymphohistiocytosis 20.67 18.57 37 37514 21800 79685037
Heart rate decreased 20.67 18.57 4 37547 70312 79636525
Phlebitis 20.50 18.57 23 37528 8807 79698030
Staphylococcal bacteraemia 20.50 18.57 27 37524 12191 79694646
Emphysematous cholecystitis 20.44 18.57 5 37546 61 79706776
Urticaria 20.29 18.57 35 37516 185166 79521671
Fungal infection 20.24 18.57 54 37497 41694 79665143
Wrong technique in product usage process 20.10 18.57 5 37546 73870 79632967
Osteoarthritis 20.03 18.57 8 37543 87301 79619536
Injection site vasculitis 20.02 18.57 4 37547 17 79706820
Isocitrate dehydrogenase gene mutation 19.98 18.57 3 37548 0 79706837
Medication error 19.98 18.57 4 37547 68638 79638199
Aspiration bone marrow abnormal 19.88 18.57 6 37545 167 79706670
Rhabdomyolysis 19.81 18.57 12 37539 103119 79603718
Neutropenic infection 19.75 18.57 13 37538 2414 79704423
Dry skin 19.71 18.57 4 37547 67991 79638846
Blast cell count decreased 19.66 18.57 4 37547 19 79706818
Hepatic enzyme increased 19.56 18.57 35 37516 182575 79524262
Bradycardia 19.51 18.57 21 37530 135536 79571301
Anal fissure 19.51 18.57 21 37530 7682 79699155
Thrombocytosis 19.44 18.57 22 37529 8504 79698333
Anal infection 19.42 18.57 6 37545 181 79706656
Rhinorrhoea 19.11 18.57 6 37545 76068 79630769
Swelling face 19.03 18.57 5 37546 71207 79635630
Graft versus host disease in lung 18.81 18.57 9 37542 903 79705934
Seizure 18.65 18.57 38 37513 188796 79518041

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01BC07 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
ANTIMETABOLITES
Pyrimidine analogues
FDA MoA N0000000233 Nucleic Acid Synthesis Inhibitors
FDA EPC N0000175595 Nucleoside Metabolic Inhibitor
CHEBI has role CHEBI:35610 antineoplastic agents
MeSH PA D000963 Antimetabolites
MeSH PA D000964 Antimetabolites, Antineoplastic
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D009676 Noxae

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute myeloid leukemia, disease indication 91861009
Myelodysplastic syndrome indication 109995007
Chronic myelomonocytic leukemia indication 127225006
Hepatic failure contraindication 59927004
Kidney disease contraindication 90708001 DOID:557
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Breastfeeding (mother) contraindication 413712001
Advanced Malignant Neoplasm of Liver contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.32 acidic
pKa2 12.92 acidic
pKa3 13.79 acidic
pKa4 4.43 Basic
pKa5 2.98 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
200MG ONUREG BRISTOL N214120 Sept. 1, 2020 RX TABLET ORAL 8846628 June 3, 2030 CONTINUED TREATMENT OF ADULTS WITH ACUTE MYELOID LEUKEMIA WHO ACHIEVED FIRST COMPLETE REMISSION (CR) OR CR WITH INCOMPLETE BLOOD COUNT RECOVERY FOLLOWING INTENSIVE INDUCTION CHEMOTHERAPY AND ARE NOT ABLE TO COMPLETE INTENSIVE CURATIVE THERAPY
300MG ONUREG BRISTOL N214120 Sept. 1, 2020 RX TABLET ORAL 8846628 June 3, 2030 CONTINUED TREATMENT OF ADULTS WITH ACUTE MYELOID LEUKEMIA WHO ACHIEVED FIRST COMPLETE REMISSION (CR) OR CR WITH INCOMPLETE BLOOD COUNT RECOVERY FOLLOWING INTENSIVE INDUCTION CHEMOTHERAPY AND ARE NOT ABLE TO COMPLETE INTENSIVE CURATIVE THERAPY

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
200MG ONUREG BRISTOL N214120 Sept. 1, 2020 RX TABLET ORAL Sept. 1, 2023 NEW PRODUCT
300MG ONUREG BRISTOL N214120 Sept. 1, 2020 RX TABLET ORAL Sept. 1, 2023 NEW PRODUCT
100MG/VIAL VIDAZA BRISTOL-MYERS N050794 May 19, 2004 RX POWDER INTRAVENOUS, SUBCUTANEOUS May 20, 2025 TREATMENT OF PEDIATRIC PATIENTS AGED ONE MONTH AND OLDER WITH NEWLY DIAGNOSED JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML)
200MG ONUREG BRISTOL N214120 Sept. 1, 2020 RX TABLET ORAL Sept. 1, 2027 INDICATED FOR CONTINUED TREATMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO ACHIEVED FIRST COMPLETE REMISSION (CR) OR COMPLETE REMISSION WITH INCOMPLETE BLOOD COUNT RECOVERY (CRI) FOLLOWING INTENSIVE INDUCTION CHEMOTHERAPY AND ARE NOT ABLE TO COMPLETE INTENSIVE CURATIVE THERAPY
300MG ONUREG BRISTOL N214120 Sept. 1, 2020 RX TABLET ORAL Sept. 1, 2027 INDICATED FOR CONTINUED TREATMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO ACHIEVED FIRST COMPLETE REMISSION (CR) OR COMPLETE REMISSION WITH INCOMPLETE BLOOD COUNT RECOVERY (CRI) FOLLOWING INTENSIVE INDUCTION CHEMOTHERAPY AND ARE NOT ABLE TO COMPLETE INTENSIVE CURATIVE THERAPY
100MG/VIAL VIDAZA BRISTOL-MYERS N050794 May 19, 2004 RX POWDER INTRAVENOUS, SUBCUTANEOUS May 20, 2029 TREATMENT OF PEDIATRIC PATIENTS AGED ONE MONTH AND OLDER WITH NEWLY DIAGNOSED JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML)

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
DNA (cytosine-5)-methyltransferase 1 Enzyme INHIBITOR IC50 6.52 CHEMBL CHEMBL
DNA (cytosine-5)-methyltransferase 3A Enzyme INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
4021468 VUID
N0000148852 NUI
D03021 KEGG_DRUG
1251 RXNORM
C0004475 UMLSCUI
CHEBI:2038 CHEBI
5AE PDB_CHEM_ID
CHEMBL1489 ChEMBL_ID
D001374 MESH_DESCRIPTOR_UI
DB00928 DRUGBANK_ID
6796 IUPHAR_LIGAND_ID
4520 INN_ID
M801H13NRU UNII
9444 PUBCHEM_CID
412328000 SNOMEDCT_US
412329008 SNOMEDCT_US
88551000 SNOMEDCT_US
4021468 VANDF
18639 MMSL
205981 MMSL
53994 MMSL
d05293 MMSL
008661 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 0143-9606 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 24 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 0143-9606 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 24 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 0781-3253 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg SUBCUTANEOUS NDA AUTHORIZED GENERIC 28 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 0781-3253 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg SUBCUTANEOUS NDA AUTHORIZED GENERIC 28 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 0781-3253 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg SUBCUTANEOUS NDA AUTHORIZED GENERIC 28 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 0781-9253 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg SUBCUTANEOUS NDA AUTHORIZED GENERIC 28 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 0781-9253 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg SUBCUTANEOUS NDA AUTHORIZED GENERIC 28 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 0781-9253 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg SUBCUTANEOUS NDA AUTHORIZED GENERIC 28 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 16714-578 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 25 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 16714-578 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 25 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 16714-927 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg SUBCUTANEOUS ANDA 24 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 16729-306 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 26 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 16729-306 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 26 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 16729-306 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 26 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 43598-143 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg SUBCUTANEOUS ANDA 25 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 43598-143 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg SUBCUTANEOUS ANDA 25 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 43598-305 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg SUBCUTANEOUS ANDA 25 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 43598-305 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg SUBCUTANEOUS ANDA 25 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 43598-465 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg SUBCUTANEOUS ANDA 25 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 43598-465 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg SUBCUTANEOUS ANDA 25 sections
AZACITIDINE AZACITIDINE HUMAN PRESCRIPTION DRUG LABEL 1 43598-678 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 24 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 43817-906 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg SUBCUTANEOUS ANDA 28 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 51991-797 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg SUBCUTANEOUS ANDA 30 sections
Azacitidine HUMAN PRESCRIPTION DRUG LABEL 1 51991-797 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg SUBCUTANEOUS ANDA 30 sections
AZACITIDINE Human Prescription Drug Label 1 55150-393 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 27 sections
VIDAZA HUMAN PRESCRIPTION DRUG LABEL 1 59572-102 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS NDA 27 sections
VIDAZA HUMAN PRESCRIPTION DRUG LABEL 1 59572-102 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS NDA 27 sections
VIDAZA HUMAN PRESCRIPTION DRUG LABEL 1 59572-102 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS NDA 27 sections
ONUREG HUMAN PRESCRIPTION DRUG LABEL 1 59572-730 TABLET, FILM COATED 200 mg ORAL NDA 31 sections
ONUREG HUMAN PRESCRIPTION DRUG LABEL 1 59572-730 TABLET, FILM COATED 200 mg ORAL NDA 31 sections